Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and ZR² in Relapsed/Refractory Follicular Lymphoma
NCT07418190Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, zanubrutinib, rituximab and lenalidomide in follicular lymphoma (FL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Complete Response Rate. Started Feb 2026; status: recruiting.
02
Drugs
tislelizumabzanubrutinibrituximablenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07418190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07418190.